Digoxin pharmacokinetics, bioavailability, efficacy, and dosage regimens in the horse. 1980

C Button, and D R Gross, and J T Johnston, and G J Yakatan

The pharmacokinetics of IV administered digoxin and the bioavailability of intragastrically administered powdered digoxin tables suspended in water were investigated in 6 clinically normal adult horses by 125I radioimmunoassay. The effect of 3 to 5 sequential IV doses of 5 micrograms of digoxin/kg of body weight at 2-hour intervals on a left ventricular index of contractility (Vmax) was assessed in 5 clinically normal horses. Standard pharmacokinetic equations and mean pharmacokinetic variables were used to derive parenteral and oral (loading and maintenance) doses for digoxin in horses. The calculated dosage regimens were administered and resulting plasma digoxin concentrations were monitored in 5 horses and 1 pony. Digoxin disposition after IV injection was triexponential. A rapid distributive phase with a half life (t 1/2 of 15 minutes was followed by a slow distributive phase with a t 1/2 of 4.1 hours. The biological disposition t 1/2 was 23.1 hours. The volume of distribution by extrapolation was 6.79 L/kg of body weight and 4.89 L/kg by the area method. The average bioavailability estimate for intragastrically administered digoxin was 19.2%. The Vmax increased significantly (P < 0.01) after IV digoxin administration. Greatest changes in Vmax were recorded after the first 2 injections (5 micrograms of digoxin/kg) corresponding to plasma digoxin concentrations of 0.83 and 1.68 ng/ml. Doses of digoxin were calculated as follows: IV loading 14, IV maintenance 7, oral loading 70, and oral maintenance 35 micrograms/kg/24 hours. When these doses were given to a group of horses, plasma digoxin concentrations measured 12 and 24 hours after administrated were mostly in the proposed therapeutic, nontoxic range of 0.5 to 2.0 ng/ml.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D009200 Myocardial Contraction Contractile activity of the MYOCARDIUM. Heart Contractility,Inotropism, Cardiac,Cardiac Inotropism,Cardiac Inotropisms,Contractilities, Heart,Contractility, Heart,Contraction, Myocardial,Contractions, Myocardial,Heart Contractilities,Inotropisms, Cardiac,Myocardial Contractions
D004077 Digoxin A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666) Digacin,Digitek,Digoregen,Digoxina Boehringer,Digoxine Nativelle,Dilanacin,Hemigoxine Nativelle,Lanacordin,Lanicor,Lanoxicaps,Lanoxin,Lanoxin-PG,Lenoxin,Mapluxin,Boehringer, Digoxina,Lanoxin PG,Nativelle, Digoxine,Nativelle, Hemigoxine
D005260 Female Females
D006736 Horses Large, hoofed mammals of the family EQUIDAE. Horses are active day and night with most of the day spent seeking and consuming food. Feeding peaks occur in the early morning and late afternoon, and there are several daily periods of rest. Equus caballus,Equus przewalskii,Horse, Domestic,Domestic Horse,Domestic Horses,Horse,Horses, Domestic
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities

Related Publications

C Button, and D R Gross, and J T Johnston, and G J Yakatan
October 1973, British medical journal,
C Button, and D R Gross, and J T Johnston, and G J Yakatan
January 1983, Clinical pharmacy,
C Button, and D R Gross, and J T Johnston, and G J Yakatan
April 1979, British journal of clinical pharmacology,
C Button, and D R Gross, and J T Johnston, and G J Yakatan
January 1988, M.D. computing : computers in medical practice,
C Button, and D R Gross, and J T Johnston, and G J Yakatan
October 1985, American journal of veterinary research,
C Button, and D R Gross, and J T Johnston, and G J Yakatan
April 2002, Antimicrobial agents and chemotherapy,
C Button, and D R Gross, and J T Johnston, and G J Yakatan
August 1975, British medical journal,
C Button, and D R Gross, and J T Johnston, and G J Yakatan
September 1978, International journal of clinical pharmacology and biopharmacy,
C Button, and D R Gross, and J T Johnston, and G J Yakatan
January 1990, Annales de recherches veterinaires. Annals of veterinary research,
C Button, and D R Gross, and J T Johnston, and G J Yakatan
October 1974, Journal of clinical pharmacology,
Copied contents to your clipboard!